A House of Lords report reveals that obesity is now the second leading health risk in England after tobacco. The Committee calls for urgent government action to overhaul the food system and reduce obesity rates.

New AI-powered research suggests that GLP-1 drugs, commonly used for diabetes and obesity, could prevent up to 34,000 heart attacks and strokes annually by offering cardiovascular benefits to millions of Americans.

Eli Lilly reduces the price of its obesity medication, Zepbound®, offering discounted single-dose vials to expand access for self-pay patients with an on-label prescription. Learn more about this cost-cutting initiative.

Eli Lilly's tirzepatide shows a 94% reduction in diabetes risk and significant weight loss in adults with pre-diabetes and obesity, according to a three-year study.

Explore the shift in GLP-1 drug use as a growing number of non-diabetics turn to these medications for weight loss. Understand the new trends and their impact on diabetes care.

A recent ukactive survey reveals that 85% of UK adults prefer the Government to invest in long-term obesity prevention rather than weight-loss drugs. Discover public opinions on health priorities, mental health support, and the role of gyms in healthcare.

Discover how Ozempic and other GLP-1 agonists may reduce the risk of obesity-associated cancers in a recent study of obese patients. Learn more about the potential cancer-preventive effects of these diabetes medications.

Combining GLP-1 drugs like liraglutide with exercise helps maintain bone health during weight loss, according to a recent study. Learn how this approach can balance weight loss and bone density preservation.

Top wellness leaders from CrossFit, Sweetgreen, Thrive Market, and more form End Chronic Disease, an advocacy group promoting exercise, healthy eating, and lifestyle changes to combat chronic illness and shift healthcare priorities.

Form Health, a leading provider of science-based obesity care in the U.S., secures $38 million in Series B funding to expand enterprise partnerships, hire ABOM-certified physicians, and enhance telehealth technology.

New WHO study reveals 31% of adults, about 1.8 billion people, are physically inactive, increasing health risks and urging global action. Discover the latest insights and trends in physical activity.

Discover how Nestlé Health Science is addressing the growing GLP-1 medication market with their new nutrition platform and Vital Pursuit food line, designed to support weight management and wellness.

New research from the University of Aberdeen reveals how physical fitness influences the body's metabolism of saturated fat. Discover how exercise impacts fat utilization and improves overall metabolic health.

Discover strategies to mitigate the high costs of discontinuing GLP-1 medications. Learn how employers can plan for effective weight management and ensure long-term adherence.

Discover the latest on Peloton's leadership changes and workforce adjustments, including CEO Barry McCarthy's transition to a strategic advisor and a 15% reduction in staff due to decreased demand for fitness equipment post-pandemic.

Explore the latest study on obesity treatments in the Obesity journal, analyzing the effectiveness of traditional diets, GLP-1 receptor agonists like semaglutide and tirzepatide, and surgical options such as Roux-en-Y gastric bypass. Learn how these interventions impact weight-loss plateaus.

Discover the transformative findings from the latest research on the best time to exercise for individuals battling obesity. Uncover how timing your workouts can significantly enhance health benefits and combat obesity-related risks, according to a groundbreaking study. Optimize your exercise routine for maximum impact.

Discover how genetics affect your exercise needs for obesity prevention. A groundbreaking study reveals why some need to walk more steps daily based on their genetic risk. Learn how personalized step counts can revolutionize obesity management.

Explore the Obesity Bill of Rights: An initiative aimed at enhancing access to quality obesity care for Americans. Learn more about this significant healthcare development.

Explore the groundbreaking study on semaglutide, a glucagon-like peptide-1 receptor agonist, and its potential cardiovascular benefits for individuals with preexisting cardiovascular conditions and overweight or obesity without diabetes. Discover insights into the 20% reduction in serious heart problems associated with Wegovy, Novo Nordisk's obesity drug. The study, published in The New England Journal of Medicine, highlights the weight loss and fitness implications, with the pharmaceutical company urging the FDA to acknowledge Wegovy's heart benefits. Delve into the safety considerations and implications for health insurers, as this research shapes perceptions of obesity drugs and their potential coverage.